Physician profile
Danielle M Doyle
NPI 1508882390
$1,010.88
in general payments reported to CMS, 2019-2025
19 companies · $462 in 2025
The $462 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $107 · 2022: $158 · 2023: $284 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $745.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $171.76 | 2022-2025 | Piqray, Kisqali |
| Gilead Sciences, INC. | $123.92 | 2021-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $114.07 | 2022-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Genzyme Corporation | $104.38 | 2021-2023 | |
| Astrazeneca Pharmaceuticals Lp | $79.19 | 2021-2025 | Enhertu |
| Eisai INC. | $75.95 | 2025 | |
| Pfizer INC. | $57.66 | 2023-2025 | |
| Glaxosmithkline, LLC. | $57.33 | 2021-2025 | Zejula |
| Takeda Pharmaceuticals U.S.A., INC. | $42.06 | 2025 | Fruzaqla |
| Genentech USA, INC. | $26.40 | 2025 | Lunsumio |
| Abbvie INC. | $21.72 | 2023 | Venclexta |
| Seagen INC. | $20.08 | 2022 | |
| Celgene Corporation | $19.61 | 2021 | |
| Genmab U.S., INC. | $18.95 | 2025 | Tivdak |
| Janssen Biotech, INC. | $18.11 | 2023 | Tecvayli |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $16.14 | 2025 | |
| Daiichi Sankyo INC. | $15.65 | 2025 | Datroway |
| Astellas Pharma US INC | $14.76 | 2022 | |
| Amgen INC. | $13.14 | 2023 | Kyprolis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.